The global point-of-care glucose testing market size was valued at USD 3.1 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 4.1% from 2022 to 2030. The growing geriatric population, the ability of point-of-care (POC) diagnostic tests to deliver immediate results, thus providing improved patient care, and rising market penetration of Electronic Medical Records (EMRs) are among the high-impact rendering drivers of this market. The shortage of skilled staff, especially in the field of diagnostics, is also expected to increase the market penetration of glucose POC diagnostic products. The market is expected to gain momentum as the presence of diabetes increases the risk of mortality from COVID-19.
Thus, diabetes management is one of the key priorities among healthcare professionals to limit the mortality rate. According to a survey by the Diabetes Research Foundation, diabetes increases the risk of a fatal outcome by 50% among COVID-19 patients. The growing awareness about diabetes management, poor healthcare access, scarcity of healthcare professionals, and the highest global prevalence recorded in Asian countries are likely to increase the adoption of PoC glucose testing solutions. This, in turn, creates an opportunity to reduce the healthcare burden by improving patient outcomes.
The introduction of favorable regulatory policies aimed at promoting PoC glucose diagnostics is expected to serve as a high-impact rendering driver for the market. For example, in the U.S., the implementation of Clinical Laboratory Improvement Amendments (CLIA) is expected to boost usage rates during the forecast period. CLIA-waived tests are approved for use by healthcare providers operating in nontraditional laboratory sites, such as emergency rooms, physician offices, pharmacy clinics, health department clinics, and other healthcare facilities. The prevalence of diabetes is increasing worldwide, which is expanding the patient pool for the market.
Furthermore, the presence of unmet medical needs for diagnosis and management of diabetes and the increase in patient awareness are expected to boost the demand for POC diagnostics. According to the International Diabetes Federation, an estimated 537 million people had diabetes in 2021, and the number is projected to increase to 643 million by 2030 and 783 million by 2045. The healthcare industry is focusing on shorter hospital stays, better acute care, and the expansion of outlying surgical centers, which has consequently increased the demand for Short Turn-Around Testing (STAT). POC management solutions allow patients and healthcare providers to easily collect, share, and manage specimens to meet regulatory requirements.
The others product segment accounted for the largest share of more than 54% of the global revenue in 2021 and will continue expanding at a steady CAGR during the forecast period. POC monitoring devices allow home-based self-monitoring of blood glucose levels and help patients perform routine activities with ease. These devices are also being used in inpatient settings as they are easy to use while offering quick results. Several glucose meters have been launched in the industry to suffice the significant need for diabetes monitoring technologies across hospitals, clinics, and other medical settings.
The Accu-Chek Inform II segment held the second-largest share in 2021. The FreeStyle Lite product segment is expected to witness the fastest growth rate over the forecast period. FreeStyle Lite is offered by Abbott and is available in discreet size with an in-built portlight and backlight, which makes it user-friendly for patients with a busy lifestyle. The product is used for measuring blood sugar from samples collected from fingers, forearm, hand, upper arm, and thigh. It is recommended to use the FreeStyle Lite meter only with the FreeStyle control solution and testing strips as the usage of other control solutions and test strips can yield inaccurate results.
North America dominated the global market in 2021. The regional market accounted for the largest share of over 40% of the overall revenue in the same year. It is expected to maintain its lead even during the forecast period. This region is home to several key market players, such as Abbott, Nova Biomedical, and Prodigy Diabetes Care, LLC. This has increased the availability of glucose testing products, thereby contributing to the revenue generation of the regional market. In addition, higher healthcare expenditure by governments on diabetes management is one of the factors responsible for the regional market growth.
The adoption of POC tests is rapidly increasing owing to their associated advantages, such as fast, easy, and mobile diagnosis and self-monitoring. These products facilitate diagnosis and monitoring for patients at hospitals, health assessment centers, clinics, and homes. Rapidly developing healthcare infrastructure and the high prevalence of diabetes are the key factors expected to drive the market in Asia Pacific. Furthermore, a rise in the adoption of miniaturized models and various measures being taken for reducing stays in hospitals and clinics are expected to boost the product demand. The adoption of POC glucose diagnostics in Operating Rooms (ORs), emergency rooms, Intensive Care Units (ICUs), path labs, and hospitals is expected to increase owing to the early and efficient delivery of results.
The market is highly fragmented with the presence of many large-, small-, and medium-scale vendors. Key players are focusing on multiple growth strategies, such as new product launches, expansions, collaborations, partnerships, and acquisitions. In June 2020, Tandem Diabetes Care and Abbott finalized an agreement to commercialize and develop an integrated diabetes solution that combines Tandem’s insulin delivery system and Abbott’s CGM technology. Some prominent players in the global point-of-care glucose testing market include:
F. Hoffmann-La Roche Ltd.
Abbott
Nipro
PlatInium Equity Advisors, LLC (Lifescan, Inc.)
Nova Biomedical
ACON Laboratories
Trividia Health, Inc.
Prodigy Diabetes Care, LLC
Bayer AG/Ascensia Diabetes Care Holdings AG
EKF Diagnostics
Report Attribute |
Details |
Market size value in 2022 |
USD 3.27 billion |
Revenue forecast in 2030 |
USD 4.5 billion |
Growth rate |
CAGR of 4.1% from 2022 to 2030 |
Base year for estimation |
2021 |
Historical data |
2018 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, end use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Russia; China; Japan; India; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; Colombia; Saudi Arabia; South Africa; UAE |
Key companies profiled |
F. Hoffmann-La Roche Ltd.; Abbott; Nipro; PlatInium Equity Advisors, LLC (Lifescan, Inc.); Nova Biomedical; ACON Laboratories; Trividia Health, Inc.; Prodigy Diabetes Care, LLC; Bayer AG/Ascensia Diabetes Care Holdings AG; EKF Diagnostics |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global point-of-care glucose testing market report on the basis of product, end use and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Accu Check Aviva Meter
Onetouch Verio Flex
i-STAT
Freestyle Lite
Bayer CONTOUR Blood Glucose Monitoring System
True Metrix
Accu-Chek Inform II
StatStrip
Others
End Use Outlook (Revenue, USD Million, 2018-2030)
Hospital
Home settings
Diagnostic centres
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Russia
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East and Africa
South Africa
Saudi Arabia
UAE
b. The global point-of-care glucose testing market size was estimated at USD 3.1 billion in 2021 and is expected to reach USD 3.2 billion in 2022.
b. The global point-of-care glucose testing market is expected to grow at a compound annual growth rate of 4.1% from 2022 to 2030 to reach USD 4.5 billion by 2030.
b. North America dominated the point-of-care glucose testing market with a share of 40.2% in 2021. This is attributable to the presence of key players such as Abbott, Nova Biomedical, and Prodigy Diabetes Care, LLC.
b. Some key players operating in the point-of-care glucose testing market include F. Hoffmann-La Roche Ltd., Abbott, Nipro, Nova Biomedical, ACON Laboratories, Inc., Trividia Health, Inc., Prodigy Diabetes Care, LLC, Bayer AG/Ascensia Diabetes Care Holdings AG, and EKF Diagnostics.
b. Key factors that are driving the point-of-care glucose testing market growth include the increasing diabetes population and technological population.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.